Aerami Therapeutics and FoxWayne Enterprises Acquisition Mutually Agree to Terminate Merger Deal

FoxWayne

Aerami Therapeutics Holdings and FoxWayne Enterprises Acquisition announced that they have mutually agreed to terminate their previously announced business combination agreement.

The companies cited “current unfavorable market conditions” for the decision. Announced in December, the deal was expected to provide Aerami with up to $250 million.

FoxWayne has until April 22 to complete a deal unless the deadline is extended by another three months with a cash infusion of 2.5 cents per share into the trust account.

Aerami is a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases. Read more.

Total
0
Shares
Related Posts
Read More

Parabellum Terminates EnOcean GmbH Deal, will Dissolve

Parabellum shareholders in December approved an extension until September to close the deal, although redemptions were heavy. The NYSE in February suspended trading in Parabellum stock because the SPAC had fallen below the minimum $40 million market cap to remain on the exchange.